Chronic gastritis Medical Services in China

Chronic gastritis is a persistent, long-term inflammatory condition of the gastric mucosa, characterized by histological evidence of chronic inflammatory cell infiltration—primarily lymphocytes and plasma cells—often accompanied by glandular atrophy, intestinal metaplasia, or dysplasia in advanced cases. Unlike acute gastritis, which presents with sudden, transient symptoms, chronic gastritis develops insidiously over months to years and may remain asymptomatic for extended periods. Its pathogenesis is multifactorial: Helicobacter pylori infection accounts for approximately 80–90% of cases globally and triggers sustained immune-mediated mucosal injury through virulence factors (e.g., CagA, VacA) and host genetic susceptibility. Other key mechanisms include autoimmune gastritis (targeting parietal cells and intrinsic factor, leading to pernicious anemia), long-term use of NSAIDs or aspirin (disrupting prostaglandin-mediated mucosal defense), bile reflux, chronic alcohol consumption, smoking, and systemic conditions such as Crohn’s disease or sarcoidosis. Epidemiologically, chronic gastritis affects an estimated 50% of the global adult population, with prevalence rising sharply with age—reaching 70–80% in individuals over 60 years. H. pylori seroprevalence remains particularly high in low- and middle-income countries (>70%), while autoimmune and NSAID-related subtypes predominate in Western aging populations. Major modifiable risk factors include untreated H. pylori infection, habitual NSAID use, smoking, excessive alcohol intake, poor dietary habits (e.g., high-salt, smoked, or nitrate-rich foods), and chronic psychological stress. Non-modifiable risks include older age, female sex (for autoimmune gastritis), and genetic polymorphisms in IL-1β and TNF-α genes. Although many patients are asymptomatic, symptomatic individuals commonly report nonspecific upper gastrointestinal complaints—including postprandial epigastric discomfort, early satiety, nausea, bloating, and occasional anorexia. Importantly, chronic gastritis significantly impacts quality of life: longitudinal studies show reduced physical functioning, increased anxiety and depression scores, impaired work productivity, and diminished social engagement—particularly among those with persistent symptoms or complications like iron-deficiency anemia or vitamin B12 deficiency. In a subset of patients, especially those with atrophic gastritis and intestinal metaplasia, there is an elevated risk of gastric adenocarcinoma (up to 6-fold higher over 10–20 years), underscoring the importance of endoscopic surveillance in high-risk groups. Early diagnosis via upper endoscopy with targeted biopsies—and accurate histopathological classification using the Updated Sydney System—is essential for risk stratification and personalized management.

Chronic gastritis is a persistent inflammatory condition of the gastric mucosa, often resulting from long-standing Helicobacter pylori infection, autoimmune mechanisms, bile reflux, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), or chronic alcohol consumption. Its clinical presentation varies widely—from asymptomatic endoscopic findings to nonspecific symptoms such as epigastric discomfort, early satiety, postprandial bloating, nausea, and occasionally iron-deficiency anemia or vitamin B12 deficiency in atrophic or autoimmune subtypes. Accurate diagnosis relies on upper gastrointestinal endoscopy with targeted biopsies for histopathological assessment, H. pylori testing (via rapid urease test, histology, stool antigen assay, or urea breath test), and serologic evaluation when autoimmune gastritis is suspected.

Conservative treatment forms the cornerstone of management and emphasizes lifestyle and dietary modification alongside risk factor mitigation. Patients are advised to avoid known gastric irritants—including NSAIDs, aspirin, corticosteroids, alcohol, tobacco, and highly spiced, acidic, or fried foods. Eating smaller, more frequent meals helps reduce gastric distension and acid exposure. Stress reduction techniques—such as cognitive behavioral therapy, mindfulness-based stress reduction, or regular physical activity—are recommended given the bidirectional relationship between psychological stress and gastric motility/acid secretion. Weight optimization is encouraged in patients with gastroesophageal reflux–associated gastritis, and elevation of the head of the bed may be beneficial in those with nocturnal symptoms suggestive of bile or acid reflux. Importantly, conservative measures must be individualized: for instance, patients with autoimmune gastritis require lifelong monitoring for pernicious anemia and osteoporosis but do not benefit from acid suppression alone; whereas those with reflux gastritis may respond well to positional and dietary adjustments.

Pharmacotherapy is tailored to etiology and symptom burden. First-line treatment for H. pylori–positive chronic gastritis is eradication therapy, typically a 14-day bismuth quadruple regimen (proton pump inhibitor [PPI] twice daily, bismuth subsalicylate, tetracycline, and metronidazole) or a high-dose dual therapy (PPI four times daily plus amoxicillin). Clarithromycin-based triple therapy is no longer recommended in most regions due to widespread resistance (>20% in China). For symptomatic relief in H. pylori–negative cases, PPIs (e.g., esomeprazole 20–40 mg once daily) remain first-line for reducing acid-mediated mucosal injury and promoting healing. Histamine-2 receptor antagonists (e.g., famotidine) offer milder acid suppression and may be used for intermittent or mild symptoms. Sucralfate—a cytoprotective agent—forms a viscous barrier over erosions and enhances mucosal defense, particularly useful in NSAID-induced or bile-reflux gastritis. In autoimmune gastritis, replacement therapy is essential: intramuscular or high-dose oral vitamin B12 (1000 µg weekly initially, then monthly maintenance) corrects deficiency and prevents irreversible neurologic sequelae; iron supplementation (oral ferrous sulfate or intravenous ferric carboxymaltose) addresses concomitant iron deficiency. Prokinetic agents (e.g., domperidone or low-dose erythromycin) may be considered in patients with documented gastroparesis contributing to symptoms.

Surgical intervention is exceedingly rare in chronic gastritis and reserved only for complications unresponsive to medical therapy. Indications include refractory bleeding from severe atrophic or erosive gastritis (requiring endoscopic hemostasis failure), gastric outlet obstruction secondary to fibrotic stricture (managed via endoscopic balloon dilation or, rarely, antrectomy), or suspicion of dysplasia or early gastric cancer on surveillance biopsies—prompting definitive resection (endoscopic submucosal dissection or laparoscopic gastrectomy). Surgery is never indicated for gastritis itself but rather for its neoplastic or structural sequelae. Preoperative evaluation mandates high-definition endoscopy with chromoendoscopy and multiple random biopsies to rule out malignancy.

Treatment in China offers distinct advantages rooted in integrated clinical infrastructure, epidemiologic expertise, and innovation. Chinese tertiary hospitals—especially those affiliated with academic centers like Peking Union Medical College Hospital or Zhongshan Hospital—maintain robust H. pylori antimicrobial resistance surveillance networks, enabling real-time, region-specific antibiotic selection. Endoscopic capabilities are world-class: narrow-band imaging (NBI), linked-color imaging (LCI), and artificial intelligence–assisted detection systems significantly improve early identification of atrophy, intestinal metaplasia, and dysplasia during routine surveillance. Moreover, China’s national gastric cancer screening program (initiated in high-risk regions such as Linzhou and Shandong) has generated unparalleled longitudinal data on gastritis progression, informing evidence-based follow-up intervals (e.g., 3-year surveillance for moderate atrophy vs. annual for extensive intestinal metaplasia). Traditional Chinese Medicine (TCM) is frequently integrated under rigorous protocols: formulas such as Weikangning decoction (containing Huang Qin, Bai Zhu, and Gan Cao) have demonstrated adjunctive efficacy in reducing inflammation and improving symptom scores in randomized controlled trials published in journals like *Gut* and *Clinical Gastroenterology and Hepatology*. Importantly, this integration occurs within allopathic frameworks—TCM is prescribed only after standard diagnostic workup and never as monotherapy for confirmed H. pylori or premalignant lesions.

Recovery and long-term management hinge on adherence, surveillance, and patient education. Patients should undergo repeat endoscopy with biopsy only if initial histology reveals atrophy, intestinal metaplasia, or dysplasia—otherwise, symptom resolution with therapy suffices. H. pylori eradication must be confirmed via urea breath test or stool antigen assay ≥4 weeks after therapy completion. Nutritional counseling is critical: patients with atrophic gastritis require regular serum pepsinogen I/II ratio, gastrin-17, and ferritin assessments; those with autoimmune disease need annual B12, methylmalonic acid, and complete blood count monitoring. Smoking cessation and strict NSAID avoidance are non-negotiable. Finally, psychosocial support—including access to gastroenterology-led patient education groups and digital health platforms offering symptom diaries and medication reminders—has been shown in Chinese cohort studies to improve 12-month treatment adherence by over 35%. With comprehensive, etiology-driven care, most patients achieve durable symptom control and significantly reduced risk of progression to gastric adenocarcinoma.